Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of -73.81% and -81.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?